CALR and coronary artery disorder: The impact of calreticulin seems to be stimulus‐ and cell model‐dependent, and during ischemic heart disease, calreticulin has been identified by different groups as being associated with both cardioprotection and adverse cardiac outcomes under different circumstances (Chen, Wu, Yao, Sun, & Liu, 2011; Cook et al., 2009; Ihara, Urata, Goto, & Kondo, 2006; Karki & Fliegel, 2010; Liu et al., 2013, 2006; Liu, Zhang, Sun, & Wu, 2008; Sun et al., 2017; Wu, Zhang, Jia, & Jia, 2015; Xia et al., 2014; Xu, Liu, & Zhu, 2008; Zhang et al., 2018; Zhao, 2018).